Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	23D2015090	03/18/2019
Name of Provider or Supplier	**Street Address, City, State**	
Abbasi Dermatology	21401 Allen Rd, Woodhaven, MI	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5601	HISTOPATHOLOGY CFR(s): 493.1273(a)(f) (a) As specified in 493.1256(e)(3), fluorescent and immunohistochemical stains must be checked for positive and negative reactivity each time of use. For all other differential or special stains, a control slide of known reactivity must be stained with each patient slide or group of patient slides. Reactions of the control slide with each special stain must be documented. (f) The laboratory must document all control procedures performed, as specified in this section. This STANDARD is not met as evidenced by: . Based on observation, lack of documentation, and interview with the office manager, the laboratory failed to document the quality of the slide staining for the Hematoxylin & Eosinophil (H&E) stain for the dermatopathology testing for nine (#1 - #9) of nine patient charts reviewed. Findings include: 1. On March 18, 2019 during patient chart review, the surveyor observed the dermatological tissue specimen processing was being performed at an outside laboratory. 2. No documentation was found to show the quality of the stain from the outside laboratory process was acceptable by the Laboratory Director (LD) reading the final tissue specimen slides. 3. During the interview on March 18, 2019 at approximately 11:15 AM, the LD acknowledged the stain quality of the slides was not documented.